Sichuan Goldstone Asia Pharmaceutical Inc. (SHE:300434)
China · Delayed Price · Currency is CNY 9.84
-0.22 (-2.19%)
Jun 2, 2026, 3:04 PM CST
SHE:300434 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,047 | 1,007 | 1,066 | 1,171 | 1,200 | 1,006 |
Other Revenue | 31.23 | 31.23 | 36.05 | 38.09 | 42.79 | 47.74 |
| 1,078 | 1,038 | 1,102 | 1,209 | 1,243 | 1,054 | |
Revenue Growth (YoY) | 4.59% | -5.80% | -8.84% | -2.69% | 17.95% | 35.53% |
Cost of Revenue | 436.63 | 435.38 | 473.18 | 467.99 | 480.74 | 459.56 |
Gross Profit | 641.76 | 603.02 | 629.17 | 741.21 | 761.87 | 593.94 |
Selling, General & Admin | 376.65 | 391.93 | 430.14 | 429.02 | 421.07 | 419.15 |
Research & Development | 53.39 | 55.03 | 50 | 50.01 | 39.18 | 37.45 |
Other Operating Expenses | 17.4 | 17.45 | 20.1 | 22.45 | 18.74 | 17.64 |
Operating Expenses | 449.57 | 463.72 | 500.79 | 500.6 | 481.06 | 478.49 |
Operating Income | 192.19 | 139.29 | 128.38 | 240.61 | 280.8 | 115.45 |
Interest Expense | -1.11 | -1.16 | -1.32 | -0.67 | -0.46 | -0.02 |
Interest & Investment Income | 4.01 | 3.16 | 5.34 | 12.09 | 2.74 | 2.97 |
Currency Exchange Gain (Loss) | -0.92 | -0.92 | 0.61 | 0.42 | 1.38 | -0.18 |
Other Non Operating Income (Expenses) | -2.45 | -1.47 | -3.89 | 3.28 | -7.91 | -0.46 |
EBT Excluding Unusual Items | 191.72 | 138.89 | 129.12 | 255.73 | 276.56 | 117.77 |
Impairment of Goodwill | - | - | - | -67.51 | - | -23.17 |
Gain (Loss) on Sale of Investments | 2.34 | -1.03 | -11.35 | -18.43 | -11.97 | -9.67 |
Gain (Loss) on Sale of Assets | 0.38 | 0.17 | -0.02 | 0.25 | 17.77 | -0 |
Asset Writedown | -0.53 | -0.35 | -4.87 | -0.78 | -1.4 | -2.72 |
Other Unusual Items | 15.03 | 15.09 | 9.78 | 7.76 | 9.58 | 11.34 |
Pretax Income | 208.94 | 152.78 | 122.66 | 177.02 | 290.54 | 93.54 |
Income Tax Expense | 26.76 | 24.15 | 34.1 | 56.31 | 77.49 | 27.43 |
Earnings From Continuing Operations | 182.18 | 128.62 | 88.56 | 120.71 | 213.05 | 66.1 |
Minority Interest in Earnings | 2.61 | 3 | 3.2 | 5.49 | 5.74 | 0.38 |
Net Income | 184.79 | 131.62 | 91.76 | 126.2 | 218.79 | 66.48 |
Net Income to Common | 184.79 | 131.62 | 91.76 | 126.2 | 218.79 | 66.48 |
Net Income Growth | 185.18% | 43.44% | -27.29% | -42.32% | 229.10% | - |
Shares Outstanding (Basic) | 399 | 399 | 399 | 407 | 405 | 391 |
Shares Outstanding (Diluted) | 399 | 399 | 399 | 407 | 405 | 391 |
Shares Change (YoY) | -0.05% | -0.03% | -2.00% | 0.48% | 3.60% | -2.75% |
EPS (Basic) | 0.46 | 0.33 | 0.23 | 0.31 | 0.54 | 0.17 |
EPS (Diluted) | 0.46 | 0.33 | 0.23 | 0.31 | 0.54 | 0.17 |
EPS Growth | 185.31% | 43.48% | -25.81% | -42.59% | 217.65% | - |
Free Cash Flow | 110.56 | 108.32 | 85.23 | 85.04 | 268.89 | 51.03 |
Free Cash Flow Per Share | 0.28 | 0.27 | 0.21 | 0.21 | 0.66 | 0.13 |
Dividend Per Share | 0.082 | 0.082 | 0.069 | 0.110 | - | - |
Dividend Growth | 18.84% | 18.84% | -37.27% | - | - | - |
Gross Margin | 59.51% | 58.07% | 57.07% | 61.30% | 61.31% | 56.38% |
Operating Margin | 17.82% | 13.41% | 11.65% | 19.90% | 22.60% | 10.96% |
Profit Margin | 17.14% | 12.68% | 8.32% | 10.44% | 17.61% | 6.31% |
Free Cash Flow Margin | 10.25% | 10.43% | 7.73% | 7.03% | 21.64% | 4.84% |
EBITDA | 292.49 | 240.13 | 231.35 | 334.33 | 371.87 | 202.41 |
EBITDA Margin | 27.12% | 23.13% | 20.99% | 27.65% | 29.93% | 19.21% |
D&A For EBITDA | 100.3 | 100.83 | 102.97 | 93.72 | 91.06 | 86.96 |
EBIT | 192.19 | 139.29 | 128.38 | 240.61 | 280.8 | 115.45 |
EBIT Margin | 17.82% | 13.41% | 11.65% | 19.90% | 22.60% | 10.96% |
Effective Tax Rate | 12.81% | 15.81% | 27.80% | 31.81% | 26.67% | 29.33% |
Revenue as Reported | 1,078 | 1,038 | 1,102 | 1,209 | 1,243 | 1,054 |
Advertising Expenses | - | 49.92 | 69.57 | 74.99 | 59.7 | 69.59 |